EFFICACY AND SAFETY OF BONE MARROW-DERIVED MESENCHYMAL CARDIOPOIETIC CELLS (C3BS-CQR-1) FOR THE TREATMENT OF CHRONIC ISCHEMIC HEART FAILURE

Trial Profile

EFFICACY AND SAFETY OF BONE MARROW-DERIVED MESENCHYMAL CARDIOPOIETIC CELLS (C3BS-CQR-1) FOR THE TREATMENT OF CHRONIC ISCHEMIC HEART FAILURE

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs C3BS CQR 1 (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms CHART-2
  • Sponsors Celyad
  • Most Recent Events

    • 07 Jul 2016 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2017.
    • 07 Jul 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.
    • 05 Jul 2016 Planned initiation date changed from 1 Dec 2014 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top